No Data
Independent Director of Immix Biopharma Picks Up 5.6% More Stock
Sector Update: Health Care Stocks Decline Late Afternoon
Immix Biopharma Announces Initial Data From First Four Patients In NEXICART-2 US Study; Says All Four Patients Treated With NXC-201 Normalized Disease Markers Within 30 Days Of Dosing, Of Which, Two Are Already Classified As Complete
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of Sterically-optimized CAR-T NXC-201 in Relapsed/refractory Light Chain (AL) Amyloidosis
Immix Biopharma Publishes NXC-201 Clinical Results In Journal Of Clinical Oncology
Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower
No Data